Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02591901 | Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods) | PHASE2 | COMPLETED | 48 | — | — | Apr 6, 2018 | Sep 21, 2019 | Mar 18, 2020 | 2 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Uro Vaxom | EXPERIMENTAL | Uro Vaxom, Once daily for 3 months |
| Placebo | PLACEBO_COMPARATOR | Placebo identical to main drug in shape and form |
| Name | Type | Description |
|---|---|---|
| Uro vaxom | DRUG | Prevention of recurrent symptomatic lower urinary tract infections |
| Placebo comparator | OTHER | Placebo comparator |
Inclusion Criteria: * Have a clinical diagnosis of spinal cord injury, multiple sclerosis, transverse myelitis or cauda equina damage; * Have had the diagnosis of the spinal pathology for at least 12 months; * Have not had any significant changes in the underlying condition for 12 weeks * Be living...